Brokerages Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Price Target at $36.60

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received a consensus rating of “Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $36.60.

KNSA has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th. Evercore ISI upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the sale, the chief operating officer now owns 88,975 shares of the company’s stock, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Mark Ragosa sold 8,969 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,092 shares of company stock valued at $471,609. 54.57% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of KNSA. Wellington Management Group LLP acquired a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth about $1,192,000. Dimensional Fund Advisors LP boosted its position in Kiniksa Pharmaceuticals by 31.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after buying an additional 157,741 shares during the period. Segall Bryant & Hamill LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth $675,000. Parkman Healthcare Partners LLC raised its stake in shares of Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after acquiring an additional 108,102 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Kiniksa Pharmaceuticals by 159.8% in the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock valued at $11,612,000 after purchasing an additional 382,539 shares during the period. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Trading Up 0.8 %

Shares of KNSA stock opened at $18.54 on Thursday. The stock’s 50-day moving average price is $20.67 and its 200-day moving average price is $23.25. Kiniksa Pharmaceuticals has a 12-month low of $16.56 and a 12-month high of $28.15. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -132.42 and a beta of 0.29.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The company had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company’s quarterly revenue was up 67.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.20) earnings per share. As a group, research analysts predict that Kiniksa Pharmaceuticals will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.